Skip to main content
. Author manuscript; available in PMC: 2013 Jun 1.
Published in final edited form as: J Mol Model. 2011 Nov 30;18(6):2831–2843. doi: 10.1007/s00894-011-1307-x

Fig. 5.

Fig. 5

Docking poses for FPR1 agonists (panels a–d) and non-active analogs (panel e) relative to the surface of the FPR1 binding site (left part) and amino acids Thr199, Arg201, Gly202, and Ala261 with the protein surface removed (right part)